Celgene (NASDAQ:CELG) has been given a $125.00 price objective by investment analysts at Credit Suisse Group in a note issued to investors on Monday, January 8th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective indicates a potential upside of 22.38% from the company’s current price.
A number of other brokerages have also weighed in on CELG. BMO Capital Markets raised their price objective on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a report on Friday, November 17th. Oppenheimer reiterated a “buy” rating and set a $170.00 price target on shares of Celgene in a research note on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research note on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Morgan Stanley upgraded shares of Celgene from an “underweight” rating to an “equal weight” rating in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $131.18.
Shares of Celgene (NASDAQ CELG) traded down $2.68 during mid-day trading on Monday, reaching $102.14. 7,928,973 shares of the company’s stock traded hands, compared to its average volume of 6,290,000. Celgene has a 52 week low of $94.55 and a 52 week high of $147.17. The stock has a market cap of $80,440.00, a PE ratio of 24.09, a PEG ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Several large investors have recently modified their holdings of CELG. Thompson Davis & CO. Inc. boosted its holdings in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI boosted its holdings in Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. Robecosam AG purchased a new stake in Celgene during the third quarter worth about $114,000. Guidant Wealth Advisors purchased a new stake in Celgene during the third quarter worth about $119,000. Finally, Capital Bank & Trust Co boosted its holdings in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 517 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/celgene-celg-given-a-125-00-price-target-by-credit-suisse-group-analysts/1823205.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.